Wedbush Issues Optimistic Estimate for DAWN Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Research analysts at Wedbush raised their Q2 2025 earnings estimates for shares of Day One Biopharmaceuticals in a research report issued on Wednesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.33) per share for the quarter, up from their previous forecast of ($0.44). Wedbush has a "Outperform" rating and a $25.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.47 EPS and FY2029 earnings at $1.48 EPS.

A number of other equities analysts also recently weighed in on DAWN. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research report on Tuesday, March 25th. Needham & Company LLC dropped their target price on Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $30.57.

Day One Biopharmaceuticals Stock Down 2.2%

NASDAQ:DAWN traded down $0.14 during trading hours on Friday, reaching $6.19. The company had a trading volume of 1,373,567 shares, compared to its average volume of 1,087,532. The firm has a market capitalization of $627.43 million, a PE ratio of -6.01 and a beta of -1.24. Day One Biopharmaceuticals has a one year low of $6.10 and a one year high of $17.14. The stock has a 50-day moving average of $7.58 and a two-hundred day moving average of $10.97.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.11. The business had revenue of $30.76 million during the quarter, compared to the consensus estimate of $30.28 million.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the transaction, the chief financial officer now directly owns 252,638 shares in the company, valued at $3,021,550.48. This trade represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,064 shares of company stock worth $251,925 over the last quarter. Corporate insiders own 6.20% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DAWN. Virtus ETF Advisers LLC grew its position in Day One Biopharmaceuticals by 7.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 27,296 shares of the company's stock worth $346,000 after purchasing an additional 1,805 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Day One Biopharmaceuticals by 5.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,843 shares of the company's stock worth $454,000 after buying an additional 1,894 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Day One Biopharmaceuticals in the fourth quarter valued at about $27,000. China Universal Asset Management Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 11.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company's stock valued at $271,000 after acquiring an additional 2,180 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in shares of Day One Biopharmaceuticals by 19.6% during the 1st quarter. Exchange Traded Concepts LLC now owns 14,693 shares of the company's stock worth $117,000 after purchasing an additional 2,407 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.